Good morning,
Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
Short one from me today. Live from the Digital Health Festival.
The talk of the town AI.
Almost every single booth has the words “AI”.
(Literally every single booth. I’ve counted 37 so far)
AI-integrated.
AI-enabled.
AI, AI, AI.
Is it true AI? Or just an old product with the words AI slapped on.
A couple of panel sessions are on my list for the rest of the day, including one on the adoption of aged-care technology, following my deep dive into the sector a fortnight ago.
Full Article 👉 Well... that aged poorly: Aged Care Industry Spotlight
Also, there are a handful of ASX-listed healthcare names on the floor that I’ll be touching base with.
I've just stepped out of a product demo with Kate Quirke, the CEO of Alcidion (ASX: ALC).
Alcidion sells workflow solutions to hospitals.
Kate has been selling healthcare technology to hospital systems for over thirty years.
The workflow management system she sold to Queensland Health three decades ago… is still in use today.
Such is the slow-moving nature of the industry.
But also, such is the stickiness of the client base. Once you're in, you're in.
And then there's the vendor floor…
A parade of the latest gadgets, products, and AI-enabled everything.
Will report back tomorrow with my key learnings.
But first…
The Pulse Check
Cleo Diagnostics (ASX: COV) establishes a U.S. reimbursement pathway for its ovarian cancer test, with a miscellaneous CPT code estimated at ~US$500–$900 per test. (COV)
🪑 Nice work.
Important to know that miscellaneous code doesn’t guarantee adoption, but it does help. This is the first step towards securing their own CPT code (the real prize).
CSL will present Noxopharm’s (ASX: NOX) Sofra technology platform for self-amplifying mRNA vaccines at a global influenza conference later this year. (NOX)
🪑Kept that one under wraps for a while.
Looks like CSL was one of the “big multi-billion dollar companies” evaluating NOX’s technology through an MTA.
Nyrada Inc. (ASX: NYR) reports preclinical results showing its TRPC inhibitor Xolatryp® reduces liver cancer tumour volume by 57% when combined with the standard chemotherapy drug doxorubicin. (NYR)
🪑The power of a platform technology.
EBR Systems (ASX: EBR) secures a three-year purchasing agreement with CHRISTUS Health, the ninth-largest U.S. hospital network. (EBR)
🪑That’s three “purchase agreement” announcements within the space of a week…
Good momentum, but whenever I talk to an analyst about the stock, the balance sheet is the biggest challenge. It just feels like the cap raise is coming.
Patrys (ASX: PAB) appoints CMAX as Phase 1 clinical trial site and Alithia Life Sciences as CRO for its RLS-2202 program for delirium. First dosing CYQ3. (PAB)
🪑Looking forward to this trial. I bought some shares in PAB as a small trading position.
OncoSil Medical (ASX: OSL) secures TGA approval for its OncoSil™ device, for pancreatic cancer treatment in Australia. (OSL)
Vitura Limited (ASX: VIT) announces legal proceedings initiated by former CEO Geoff Cockerill. (VIT)
🪑 Messy 🍿
See you all tomorrow,
The Armchair Analyst
